Jichish Medical: The Phase II clinical trial of CS2009 in Australia has completed its first patient enrollment.

Foundation Medicine announced today that the global multicenter Phase II clinical trial of the company's core pipeline CS2009 has enrolled its first patient in Australia. The trial is currently actively enrolling in Australia and China, with plans to expand to the United States in the future. This global multicenter Phase II trial, initiated, utilizes a multi-queue parallel expansion design, covering 15 queues and multiple solid tumor indications, focusing on the evaluation of the safety, tolerability, PK/PD characteristics, and efficacy of CS2009 as a single agent and in combination therapy.